The Psychiatry Consortium is a strategic collaboration of 2 leading medical research charities and 7 pharmaceutical companies focusing on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of the people living with mental health conditions. The Consortium is managed by the Medicines Discovery Catapult and supported by Wellcome.
The Psychiatry Consortium is currently seeking project proposals which focus on the validation of novel molecular drug targets for mental health conditions. In addition to project funding, we provide project management and delivery support and access to industry and commercial know-how.
Book a meeting with us to find out more about our upcoming funding opportunities and to discuss your research project with our team.
